Member Info for Scinv_temp

Just to clarify 2 things

1. SP was there prior to the 02/09 RNS that said LD is presenting and has never lost her spot in the agenta since I've been checking.

2. However, in July this was posted:

"Her session promises to provide valuable insights into the vaccine's new updates and trial results."

https://www.linkedin.com/posts/festivalofbiologics_festivalofbiologics-activity-7212009308102782976-g0Hx?utm_source=share

3. In LD's version of the statement it says "She has developed", while in SP's version it says "Scancell has developed"

Is this confusing? Yes. I bet it's scinvs fault

*stt

I can see str 2 years from now in the gardens of a mental institution and in a Napoleon outfit, ordering squirrels to buy TLY

"Here, we found that the PRR signaling adaptor molecules MyD88 and TRIF contribute to IFN induction and lung inflammatory pathology during B. pertussis infection. However, the PRRs Toll-like receptors (TLR) 3 and TLR4, which signal through TRIF and MyD88, respectively, played no role in IFN induction. Instead, the DNA-sensing PRRs, TLR9 and STING, were important for induction of type I/III IFN and promotion of inflammatory pathology, indicating that DNA is a major inducer of lung IFN responses in B. pertussis infection."

So Sanofi wants to avoid IFN signalling as well.

Are you sure you are not short SNG pmj?

So S

So since IL-33 activates intereferon pathway, and AZ wants to inhibit IL-33 with the support of TW, does that mean that TW is now anti-interferon? Are you short now pmj?

Fruits

2 paragraphs and 0 actual content

LMAO

Evidence:

https://www.science.org/doi/10.1126/science.aaa1578

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1475653/

Proof that SNG knew about the evidence since at least 2012:

"Defects in the production of, or response to, IFNs are associated

with an increased susceptibility to infection. For example, mice

lacking the Type I IFN are highly susceptible to infection with a

range of viruses despite an otherwise intact immune system2

.

Similarly, people with genetic defects in IFN pathways are prone

to serious life-threatening infections3"

https://synairgen.ams3.digitaloceanspaces.com/15812_sy_annualreport_2012_web.pdf

The truth is you are a joke Fruits

More BS from the cornershop worker, fruits. Anntiviral responses biomarkers are target engagement biomarkers, just to show that the drug is doing what is expected to do on the molecular level. Basic stuff. What they needed was patient stratification biomarkers (which patients would benefit most from sng001). Although it's true that in the peak of covid clinical research on that was limited, they already had a bio marker and they refused to use it because it limited the patient population. Back in 2021 when I insisted that sng should be focused on patients that 1. Low ifn levels to begin with

2. Autoantibodies against the ligands (which were mostly against ifn-a btw)

The fool that is Mrasden and Sir Fartalot said the market was too small for them.

By the way, SNG knew about the IFN deficient patients LONG before the Casanova papers, which merely showed that the deficiencies are relevant in covid, in addition to flu and other respiratory viruses that was already known YEARS AGO.

But the world was not enough for the criminally foolish SNG management

It is amasing that after so many years of reading scientific papers you still can't connect 2 dots. IL33 activates IFN signaling and these drugs *block* IL33. That should tell you enough about these companies potential interest in SNG.

They previously said that their patents prevent everyone else from using their own p38i for flu or cytokine syndrome

Hi thompi.

These patents cannot prevent anyone else from using their own p38i for the same indications that polb is targeting. JS/CF have lied to you. That's the problem.

2/2

My view is you are been taken for a ride with buzzwords and TAMs

Posted in: POLB

Price: 6.35

RE: RE: POLB 0O116 Dec 2022 14:44

And here is an example

https://patents.google.com/patent/EA039897B1/en?assignee=Hvivo&oq=Hvivo

Price: 6.35

RE: RE: POLB 0O116 Dec 2022 14:34

1. I think you need to calm because you are not thinking clearly

2. Why is polb doing an lpd challenge study even though they want to target flu? Because they ate trying to target flu induced inflammation not the virus itself.

3. What is a better surrogate model for flu induced inflammation, inhaled lps OR injected under the skin and in the bloodstream. You guessed it, its inhaled.

4. In the links that I posted you will see that they have also done ARDS trials. That is Acute Respiratory Dsitress Syndrome, it is a condition commonly induced by viruses and it is particularly critical in patients with COPD. Do you know why polb wants to test this for flu? Especially to prevent ARDS

5. Before polb/hvo (who has actually filed for the patents) people have suggested the link both for flu and for preventing inflamation from flu and other conditions. They have also done trials using very similar models that polb is using. Based on this, do you think even if it works, polb can prevent pretty much the top 20 pharmas in the world from using their own for the same?

6. Do you understand that everyone took a shot at this and failed? Your bet beeing CF will do it better than almost all pharma combined?

7. Do you understand that they are not even trialing this for flu specifically but they are using surrogate models so they can't even support their own patent so far?

8. Do you understand others have patented p38 use in flu before polb? (Link will follow)

9. Do you understand the concept of prior art and that not all patents are enforceable? Their patents (filed by hvo) are defensive, preventing others from claiming exclusivity on p38 inhibition (in general, not with whatever compound they have) not offensive (ie preventing others from doing the same).

10. Do you undestand that for all the claims they made they have published NOTHING, while all the others (meaning multibillion £ pharma) not only have done so but before they will (IF they ever publish).

Posted in: POLB

Price: 6.35

RE: RE: POLB 0O116 Dec 2022 13:57

Oh really? They have even done lps challenge trials precisely for this reason. But really, pharma has been looking to see what p38 does in inflamatory conditions for ages

https://www.cochranelibrary.com/content;jsessionid=546AAB970F4EAA4489AEF546877B1A39?templateType=related&urlTitle=%2Fcentral%2Fdoi%2F10.1002%2Fcentral%2FCN-01031511&doi=10.1002%2Fcentral%2FCN-01031511&p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&_scolariscontentdisplay_WAR_scolariscontentdisplay_action=related-content&p_p_lifecycle=0&p_p_mode=view&type=central&contentLanguage=

https://www.cochranelibrary.com/content;jsessionid=546AAB

1/2 For those who *actually* like research

Scinv_temp

Posted in: POLB

Posts: 1,243

Price: 9.95

No Opinion

RE: Exciting2 Mar 2023 10:43

The truth is you are been taken for a ride.

I have previoualy posted the numerous p38i out there that pretty much every big pharma has on the shelf.

I have also posted numerous studies that show biomarker modulation in response to p38 inhibitors and speculation on their potential role in complications in influenza and other viral infections, the vast majority of which took place long before hvivo (the original holder of polb patent on polb001) let alone polb.

A coulple of presentations back JS mentioned that their "patents" would prevent everyone else from using their own p38i which is so wrong (they can't stop anyone) its disgustingly unethical towards investors.

Now here 3 other clinical trials, 1 of which took place long before polb was even an idea, let alone a company.

Covid 19, same rational as with flu 2020

https://clinicaltrials.gov/ct2/show/NCT04394208

Similar as above

https://clinicaltrials.gov/ct2/show/NCT04511819?term=P38+mapk&draw=4&rank=28

Similar to the one polb did (lps human challenge) but from 2014

https://clinicaltrials.gov/ct2/show/NCT02211170?term=P38+mapk&draw=7&rank=51

Scinv_temp

Posted in: POLB

Posts: 1,243

Price: 9.60

No Opinion

RE: This company is going places17 Jan 2023 09:31

Here is an example of using p38i to ameliorate CRS induced by CAR T-cells.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170323/

There are obviously many examples of using p38i to prevent CRS. So much for non obviousness.

Scinv_temp

Posted in: POLB

Posts: 1,243

Price: 9.60

No Opinion

RE: This company is going places17 Jan 2023 09:08

A few notes

1. In LPS study volunteers were pretreated with the drug which does not reflect timing of treatment in influenza (you get treatment at onset or after)

2. Metabolic asset with product from AnaBio trial commencement in H1 2023 -> this is laughable the chances of initiating a clinical trial H1 with a new formulation so soon are slim at best.

3. Question of nevelty of using p38i in CRS (around 36 to 37m in the presentation) was answered in contradiction to information on slide 8 where it says CRS has been an area of interest (as discussed here before). In the second part of his answer he clarified that the distinction is shorter treatment window which is laughble and also in contradiction to "non obviousness" also in slide 8. As discussed before, peolle have suggested using p38i in flu/other respiratory viral infections and, innaddition, to prevent adverse effects in CAR T cell therapies. Only route here is to able to obtain ORPHAN drug designation which has not been discussed at all.

4. Cheeky answer to question how many companies were interested when he said a dozen, usual interest means a follow up after initial discussion but hey, this is minor compared to the rest.

My v

🤣🤣🤣

I didn't know your willy was smaller than your IQ moni. Sorry to hear that.

Ooops, make that 17 months ago :)

I do apologise, it was 5 months ago.

Scinv_temp

Posted in: POLB

Posts: 1,240

Price: 10.15 No Opinion RE: Exciting 2 Mar 2023 13:50

These are the next steps as I see them: Company says at some point that they had some interest from pharma but they asked for data specifically for the indication they are after. Meaning that for flu for example they would have to do a phase 2 specifically to prevent/treat flu complications. Because otherwise, why would they fund somebody elses asset when the could be funding their own? This means they will have to do a placing, get millions from investors and then plan and execute said phase 2 for the next 2 years or so. If that trial shows something others have not seen before (and they have tried) then they will have a chance at getting something out of it, maybe 2-3 times cost of trial and single digit royalties from sales if aforementioned pharma actually gets to approval. Another scenario is they outlicence to another small biotech or fund for 500k to 1M and low single digit royalties if the other party actually gets to the finish line. These are the only good scenarios that I can see. The bad one (and it does happen) is they ask millions from investors, spend half for a sloppy phase 2 and use the rest to keep the company going for a few more years. Imho

But here is another bit from 21 months ago.

Scinv_temp

Posted in: POLB

Posts: 1,240

Price: 6.05

No Opinion

RE: RNS out21 Dec 2022 11:25

By the way, pharma doesn't typically do validation of drug targets as a collaboration with 3rd parties . That means next step is either doing an academic collaboration with a lab for validation (in return for royalties and/funding) or paying a cro to do said validation. That means its unlikely you'll see actual pharma involved in any of their target discovery projects next year, which is what you expect, isn't it?

*Go

Stt, you are always going to be insane. I think you are well past the point of no return. But why not try and make yourself useful at least?

Ho and bash POLB or some other garbage and salvage some of the minuscule credibility you may have left.

Well well moniman. If only someone warned you 6 months ago....

Oh wait a minute, you were warned :)

You broke that contract bu calling me back. Here is another one. This is my last post until I sell. Not my fault if you brake it again.

Right here you buffoons. And C7 is right, still holding on to my shares. I'll let you know when I sell and why